ArticleJACC. Case reports2025
Fluoropyrimidines: A Cardiotoxicity Case for Caution.
Article in JACC. Case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFluoropyrimidines are widely used in cancer treatment but can cause cardiac adverse effects. CASE SUMMARY: A 57-year-old man with esophageal cancer, receiving fluoropyrimidine-based therapy, was referred for preoperative cardiac evaluation. Abnormal electrocardiogram findings raised concern for ischemia, but coronary angiography ruled out obstructive disease. Fluoropyrimidine-induced coronary vasospasm was suspected, and calcium channel blocker therapy was initiated. Five months later, after tumor recurrence, continuous fluoropyrimidine infusion was restarted without cardiology consultation, and calcium channel blocker therapy had been discontinued. The patient developed cardiogenic shock and died. WHY BEYOND THE GUIDELINES: Current guidelines provide limited recommendations for managing suspected fluoropyrimidine-induced coronary vasospasm. DISCUSSION: Fluoropyrimidine-induced coronary vasospasm poses a clinical challenge. Retreatment may be feasible if obstructive coronary artery disease is excluded, and prophylactic vasospasm therapy is administered within a structured protocol. TAKE-HOME MESSAGES: Fluoropyrimidines can cause life-threatening coronary vasospasm. With multidisciplinary care, continued therapy may be possible. Awareness among oncologists, cardiologists, primary care physicians, and patients is critical.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.